Download Free Medical Modern therapy in oncology - metastatic melanoma PowerPoint Presentation

Modern therapy in oncology - metastatic melanoma PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Familial Malignant Melanoma, which is titled "Modern therapy in oncology – metastatic melanoma", to know about melanoma (malignant melanoma), malignant neoplasm of the skin, mucosa or uvea derived from melanocytes. The presentation also talks about modern therapy in this regard.

Tags : Familial Malignant Melanoma, Modern therapy, oncology, metastatic melanoma, malignant neoplasm, skin, mucosa, uvea, melanocytes

Published on : May 18, 2021 | Views : 1857 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Modern therapy in oncology – metastatic melanoma Łukasz Kwinta
Slide 2-

Melanoma Melanoma (malignant melanoma) – malignant neoplasm of the skin, mucosa or uvea derived from melanocytes
Slide 3-

Skin melanoma - incidence The incidence of melanoma in Poland (2010): almost 1,200 in men and 1,350 in women Annually more than 100,000 cases worldwide. Melanoma represents 1% of malignant tumors and 5-7% of skin cancers The growing trend of skin melanoma incidence in both sexes – 3-fold increase over three decades Geografical differences in incidence Globally 2,4 – 3,1/100,000 South-central Asia 0,2/100,000 Australia 37/100000 (Queensland 43-56/100,000)
Slide 4-

Melanoma in USA (Surveillance, Epidemiology and End Results Program)
Slide 5-

Risk factors Exposure to UV radiation (sun, artificial source of radiation) Intensive intermittent exposure to UV (especially sunburns during chilhood) is linked to higher risk than long-term regular exposure Sunbeds Family history of melanoma (10%) Dysplastic nevus syndrome Immunosuppression
Slide 6-

Skin melanoma
Slide 7-

Diagnosis: Physical examination – examination of WHOLE skin, including „problematic” areas (hairy skin of the head, feet, interdigital spaces, genital and anal areas) Dermatoscopy and videodermatoscopy
Slide 8-

Dermatoscopy
Slide 9-

ABCD(E) Scale
Slide 10-

Glasgow seven points checklist
Slide 11-

Early diagnosis!!!
Slide 12-

Diagnosis of skin melanoma: Histopatologic examination of whole primary lesion (excisional biopsy) – no neddle biopsy!!!
Slide 13-

Treatment: Depends on: -depth of invasion (Breslow) -ulceration -mitotic activity (number of mitosis/mm2) -lymph nodes involvement -distant metastases
Slide 14-

Sentinel lymph node biopsy (excision) Sentinel node is the first lymph node in the way of lymphatic drainage Sentinel node is usually the first location of lymphatic metastases The absence of metastases in the sentinel node does not allow to exclude the presence of nodal and distant metastases (can develop as a result of blood spread)
Slide 15-

Sentinel lymph node biopsy
Slide 16-

Regional lymph nodes excision It has been shown that involvement of the sentinel node is associated with approximately 18% risk of involvement of other regional lymph nodes Regional lymph node dissection (lymphadenectomy) improves local control of disease and reduce the risk of distant metastases Removal of all possible lymph nodes draining lymph from region involved by primaty lesion
Slide 17-

Types of recurrences Local recurrence Satellite and in transit lesions Nodal recurrence Distant organs metastates
Slide 18-

Satellite and in transit lesions
Slide 19-

Qualification for further treatment by a multidisciplinary therapeutic teams Consider qualification for clinical trials Determination of BRAF V600 mutation (in metastatic or primary lesions Available therapies: CTLA-4 inhibitors (ipilimumab), PD-1 inhibitors (pembrolizumab, nivolumab), BRAF inhibitors (vemurafenib, dabrafenib) in combination with MEK inhibitors (cobimetinib, trametinib), IL2, chemotherapy, radiotherapy, surgery, T-VEC. Advanced and disseminated melanoma - treatment
Slide 20-

BRAF V600 activating mutation BRAF kinase is a serine-threonine kinase activating MEK/ERK kinases The gene is classified as protooncogene Activating mutation (oncogene) is a relatively frequently present in many types of cancer. Mutated BRAF gene is involved in the pathogenesis of melanoma by constitutive activation of MEK/ERK pathway (impact on potential for replication, angiogenesis, ability to infiltrate tissues and to metastasize, avoiding immune response and apoptosis) BRAF mutation leads to uncontrolled tumor cell proliferation
Slide 21-

RAS-RAF-MEK pathway
Slide 22-

Mutations distribution
Slide 23-

SYSTEMIC TREATMENT IN BRAF-MUTATED MELANOMA - Targeted therapies (preferred when fast response is needed – risk of visceral crisis) Vemurafenib Dabrafenib Dabrafenib+Trametinib Wemurafenib+Cobimetinib - Immunotherapy Nivolumab Pembrolizumab - Clinical trials
Slide 24-

ppt slide no 24 content not found
Slide 25-

Immunotherapy The hypothesis of immune surveillance was established in the 60s and 70s by Sir Frank Burnet Macfarlance The human immune system is constantly searching and eliminating tumor cells Progress in the understanding of the functioning of the immune system has enabled a detailed definition of immune mechanisms eliminating cancer cells Development of immunooncology
Slide 26-

Median survival of metastatic melanoma before 2011 (before approvals of immunoterapies/targeted therapies) - 6-9 months Immunological check-points inhibitors CTLA-4 inhibitor Ipilimumab (Yervoy) PD-1 inhibitor Nivolumab (Opdivo) Pembrolizumab (Keytruda) Immunotherapy
Slide 27-

Immunological synapse
Slide 28-

Immunologic checkpoints inhibitors
Slide 29-

Immuno-related adverse events
Slide 30-

Metastatic melanoma – additional possibilities of treatment - Chemotherapy DTIC, temozolomide, paclitaxel, fotemustine, multi-drugs regimens - Surgery radical resections of single metastasis in patients in good permormance status - Radiotherapy metastatic lesions of CNS, painful metastases in bones or other organs
Slide 31-

Early diagnosis!!!